CORT · NASDAQ · STOCK
Corcept Therapeutics (CORT) Stock Analysis
$113.79
52W $28.66 – $126.38
62/100
$12.73B
226.5
0.45
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is CORT Bullish or Bearish?
Bullish.
Innellis AI committee rates Corcept Therapeutics Incorporated (CORT) Buy with a composite score of 62/100
, based on 6 analysts with 67% agreement.
Last updated October 14, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +12.84 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -7.16 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. Portfolio Manager remains cautious — 2 existing position pair(s) are highly correlated already. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- P/E of 233.2 is expensive by classic value standards — Value
- Price-to-book of 11.4x prices in significant intangible value — Value
- EPS declining -62.5% YoY despite any revenue growth — Growth
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 14, 2026
Overall Committee Score
62/100
Agreement
67%
Analysts
6
Conviction
Contested
Sector Rank
Top 18%
of 192 Healthcare peers
Value Analyst
bearish
40
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 233.2 is expensive by classic value standards
Growth Analyst
neutral
57
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− EPS declining -62.5% YoY despite any revenue growth
Technical Analyst
bullish
69
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
63
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.15 across 13 articles, 14d)
Portfolio Manager
bearish
35
/ 100 · Low confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− 2 existing position pair(s) are highly correlated already
Investment Thesis Evolution
Committee score moved marginally from 64.4 to 62.2.
- New bearish signals: 1 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- Macro Analyst: score 80->65 (-15).
- News Analyst: +1 bullish signal(s).
- Portfolio Manager: score 30->35 (+5).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-13 to 2026-10-14 (1 day apart).
Technical Analysis
RSI (14)
43.9
Neutral
MACD Histogram
-0.106
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$108.50
Resistance
$117.20
Bollinger %B
0.45
Inside Bands
Price vs Moving Averages
EMA 9
$118.27
Below
EMA 21
$117.04
Below
EMA 50
$112.17
Above
EMA 200
$86.60
Above
Fundamental Analysis
Valuation
33
Growth
72
Profitability
77
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
226.5×
P/B Ratio
17.59×
PEG Ratio
-3.86
Dividend Yield
0.00%
52W High
$126.38
52W Low
$28.66
Quality & Growth
ROE
1538.3%
ROA
1191.1%
Gross Margin
9830.5%
Operating Margin
77.1%
Revenue Growth YoY
—
Debt / Equity
0.01
AI Fundamental Assessment
P/E ratio of 226.5 (rich relative to a 15-40x range); Price-to-book of 17.6x; PEG ratio of -3.9 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 15.4%; Return on assets of 11.9%; Net margin of 6.6%; Gross margin of 98.3%; Current ratio of 2.86 (healthy short-term liquidity); Debt-to-equity of 0.01; Free cash flow per share is positive (1.01); Most recent quarter beat estimates by 6958.8%; EPS growth accelerating (-250.0% -> +220.0% QoQ); Analyst estimates falling over recent quarters
Get the Full CORT Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →